Navamedic ASA
Informe acción OB:NAVA
Capitalización de mercado: NOK 431.0m
Navamedic Crecimiento futuro
Future controles de criterios 4/6 Se prevé un crecimiento anual de los beneficios y los ingresos de Navamedic de 25.5% y 12.6% por año respectivamente. Se prevé que el BPA crezca en un 1.8% al año. Se espera que la rentabilidad financiera sea de 17% en 3 años.
Información clave
25.5%
Tasa de crecimiento de los beneficios
1.8%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Pharmaceuticals 15.4% Tasa de crecimiento de los ingresos 12.6% Rentabilidad financiera futura 17.0% Cobertura de analistas Low
Última actualización 11 Nov 2024
Actualizaciones recientes sobre el crecimiento futuro
Consensus EPS estimates fall by 21% Nov 12
Consensus EPS estimates fall by 12% Aug 25
Price target decreased by 7.1% to kr45.50 Aug 14
Consensus EPS estimates increase by 24% Mar 07
Consensus EPS estimates fall by 28%, revenue upgraded Feb 27
Consensus EPS estimates increase by 10% Oct 29
Mostrar todas las actualizaciones
Consensus EPS estimates fall by 21% Nov 12
Chief Financial Officer recently bought kr476k worth of stock Nov 08
Navamedic Launches Eroxon in Finland Nov 07
New minor risk - Profit margin trend Nov 06
Third quarter 2024 earnings released Nov 01
Investor sentiment deteriorates as stock falls 17% Nov 01
Chief Executive Officer exercised options to buy kr2.2m worth of stock. Sep 11
Consensus EPS estimates fall by 12% Aug 25
Director recently bought kr1.5m worth of stock Aug 22
Second quarter 2024 earnings released: EPS: kr1.17 (vs kr0.92 loss in 2Q 2023) Aug 18
Price target decreased by 7.1% to kr45.50 Aug 14
First quarter 2024 earnings released May 02 An unknown buyer acquired unknown minority stake in Navamedic ASA (OB:NAVA) from Ingerø Reiten Investment Company As for NOK 95 million. Mar 13
Consensus EPS estimates increase by 24% Mar 07
Consensus EPS estimates fall by 28%, revenue upgraded Feb 27
New minor risk - Earnings quality Feb 18
Full year 2023 earnings released Feb 16 Navamedic ASA to Report First Half, 2024 Results on Aug 16, 2024
Third quarter 2023 earnings released Nov 06
Consensus EPS estimates increase by 10% Oct 29
Is Navamedic (OB:NAVA) Using Too Much Debt? Sep 19
Investor sentiment improves as stock rises 15% Sep 12
Consensus EPS estimates fall by 53% Aug 22
New minor risk - Financial position Aug 15
Second quarter 2023 earnings: Revenues exceed analyst expectations Aug 15
Consensus EPS estimates fall by 15% Aug 06
Consensus EPS estimates fall by 16%, revenue upgraded Jul 26
Navamedic ASA Elects Åsa Kornfeld as Members of its Board of Directors Jun 02
First quarter 2023 earnings released May 12
Price target increased by 8.7% to kr50.00 Feb 27
Here's Why Navamedic (OB:NAVA) Can Manage Its Debt Responsibly Feb 18
Full year 2022 earnings released Feb 17
Consensus EPS estimates increase by 20%, revenue downgraded Feb 10
Navamedic ASA Launches Modifast in Norway Jan 31 Navamedic ASA to Report Q3, 2023 Results on Nov 01, 2023
Price target increased to kr48.00 Nov 16
No independent directors Nov 16
Consensus EPS estimates increase by 19% Nov 10
Shareholders Can Be Confident That Navamedic's (OB:NAVA) Earnings Are High Quality Nov 09
Third quarter 2022 earnings released Nov 02
Is Navamedic (OB:NAVA) A Risky Investment? Nov 02
Consensus forecasts updated Oct 25
Price target decreased to kr44.00 Oct 24
Navamedic ASA Launches Forlaxgo® Oct 20
Consensus EPS estimates increase by 50% Aug 23
Consensus EPS estimates increase by 30% Aug 11
Chief Financial Officer exercised options to buy kr2.1m worth of stock. Jun 02
Navamedic ASA (OB:NAVA) acquired Impolin AB for SEK 55 million . Jun 02
Consensus forecasts updated May 17
First quarter 2022 earnings: Revenues exceed analyst expectations May 10
Navamedic ASA (OB:NAVA) agreed to acquire Impolin AB. May 06
Price target increased to kr50.00 Apr 27
No independent directors Apr 27
Here's Why Navamedic (OB:NAVA) Has A Meaningful Debt Burden Feb 22
Full year 2021 earnings: Revenues exceed analyst expectations Feb 18
Navamedic ASA launches SmectaGO - an innovative on-the-go product for treatment of diarrhea Feb 17
Navamedic Asa Provides Revenue Guidance for the Full Year 2021 and 2022 Dec 24
Third quarter 2021 earnings released Nov 05
We Think Navamedic (OB:NAVA) Can Stay On Top Of Its Debt Sep 04
Second quarter 2021 earnings released: EPS kr0.20 (vs kr0.037 in 2Q 2020) Aug 18
Navamedic ASA Announces the Launch of New Products in the Nordics Jun 02
Navamedic Launches Mycontrol Support in Norway, A Free-Of-Charge Patient Support Program in Collaboration with Observia, Following A Successful Launch in Sweden May 21
First quarter 2021 earnings released May 12
Is Navamedic (OB:NAVA) Using Too Much Debt? Apr 12
New 90-day high: kr29.00 Mar 02
Full year 2020 earnings released Feb 20
If You Had Bought Navamedic (OB:NAVA) Stock Three Years Ago, You Could Pocket A 166% Gain Today Feb 18
New 90-day high: kr22.60 Feb 09
Is Navamedic (OB:NAVA) Using Debt Sensibly? Dec 07 Navamedic ASA to Report Q2, 2021 Results on Aug 13, 2021
New 90-day low: kr17.45 Nov 04
New 90-day low: kr18.20 Oct 15
Chief Executive Officer exercised options to buy kr2.3m worth of stock. Oct 08
New 90-day low: kr18.50 Sep 22
Earnings released Aug 21
Previsiones de crecimiento de beneficios e ingresos OB:NAVA - Estimaciones futuras de los analistas y datos financieros pasados (NOK Millions) Fecha Ingresos Beneficios Flujo de caja libre Flujo de caja operativo Núm. de analistas medio 12/31/2026 694 44 14 29 1 12/31/2025 588 57 -7 8 2 12/31/2024 503 23 38 43 1 9/30/2024 526 20 7 9 N/A 6/30/2024 543 27 3 6 N/A 3/31/2024 511 -11 -9 -6 N/A 12/31/2023 512 3 0 2 N/A 9/30/2023 503 31 47 47 N/A 6/30/2023 454 23 31 33 N/A 3/31/2023 441 43 37 40 N/A 12/31/2022 382 29 16 18 N/A 9/30/2022 356 12 7 9 N/A 6/30/2022 327 8 2 2 N/A 3/31/2022 283 4 -8 -7 N/A 12/31/2021 278 1 -2 -1 N/A 9/30/2021 244 -7 1 2 N/A 6/30/2021 237 -6 -1 2 N/A 3/31/2021 213 -8 -4 0 N/A 12/31/2020 210 -16 -8 -3 N/A 9/30/2020 202 -22 -20 -16 N/A 6/30/2020 194 -24 -18 -15 N/A 3/31/2020 199 -26 -13 -12 N/A 12/31/2019 189 -16 12 13 N/A 9/30/2019 193 -1 1 4 N/A 6/30/2019 189 0 5 5 N/A 3/31/2019 187 10 -1 -1 N/A 12/31/2018 184 4 -38 -38 N/A 9/30/2018 177 -20 -26 -20 N/A 6/30/2018 178 -13 N/A -11 N/A 3/31/2018 222 -20 N/A 41 N/A 12/31/2017 258 -16 N/A 59 N/A 9/30/2017 294 3 N/A 43 N/A 6/30/2017 315 4 N/A 29 N/A 3/31/2017 292 -9 N/A -13 N/A 12/31/2016 274 -11 N/A -15 N/A 9/30/2016 258 -28 N/A -8 N/A 6/30/2016 254 -30 N/A -7 N/A 3/31/2016 247 -17 N/A 10 N/A 12/31/2015 248 -11 N/A 23 N/A 9/30/2015 245 -4 N/A 24 N/A 6/30/2015 242 1 N/A 8 N/A 3/31/2015 242 1 N/A -9 N/A 12/31/2014 223 -1 N/A -11 N/A 9/30/2014 204 1 N/A -12 N/A 6/30/2014 182 -2 N/A -8 N/A 3/31/2014 161 -3 N/A -16 N/A 12/31/2013 152 -1 N/A -16 N/A
Mostrar más
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (25.5% al año) de NAVA es superior a la tasa de ahorro (2.4%).
Beneficios vs. Mercado: Se prevé que los beneficios (25.5% al año) de NAVA crezcan más rápidamente que el mercado Norwegian (9.8% al año).
Beneficios de alto crecimiento: Se espera que los beneficios de NAVA crezcan significativamente en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (12.6% al año) de NAVA crezcan más rápidamente que los del mercado Norwegian (2.1% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 12.6% al año) de NAVA crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de NAVA sea baja dentro de 3 años (17%).
Descubre empresas en crecimiento Simply Wall St™ Simply Wall Street Pty Ltd Level 7, 320 Pitt Street, Sydney Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}